Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Reisman

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Paediatrics & Child Health|August 4, 2025
Impacting the physical activity confidence of children with medical conditions or disabilities: A randomized controlled trialHana Alazem, Jenna Yaraskavitch, Angelica Blais, et al.
Tijdschrift Voor Psychiatrie|November 9, 2022
[Guided discontinuation of antidepressants: approach and first results of a Dutch multidisciplinary outpatient clinic]E Dozeman, H J van der Lande, P M Bet, et al.
Journal for Immunotherapy of Cancer|April 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinomaHoward L Li, Soren Charmsaz, Benjamin J Reisman, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Paediatrics & Child Health|August 4, 2025
Impacting the physical activity confidence of children with medical conditions or disabilities: A randomized controlled trialHana Alazem, Jenna Yaraskavitch, Angelica Blais, et al.
Tijdschrift Voor Psychiatrie|November 9, 2022
[Guided discontinuation of antidepressants: approach and first results of a Dutch multidisciplinary outpatient clinic]E Dozeman, H J van der Lande, P M Bet, et al.
Journal for Immunotherapy of Cancer|April 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinomaHoward L Li, Soren Charmsaz, Benjamin J Reisman, et al.
Pageof 8